Toremifene in the treatment of breast cancer

Table 5 Frequency of serious adverse events among 499 patients with invasive breast cancer randomised to adjuvant toremifene or tamoxifen therapy[33]

	Toremifene		Tamoxifen
	Number ofpatients	%	Number ofpatients	%
Serious adverse events	72	15.7	74	16.8
Cardiac events	9	2.0	6	1.4
Myocardial infarctions	7	1.5	5	1.1
Angina pectoris	2	0.4	1	0.2
Thromboembolic events	16	3.5	26	5.9
Pulmonary embolisms	3	0.7	3	0.7
Deep vein thrombosis	8	1.7	11	2.5
Cerebrovascular events	5	1.1	12	2.7
Endometrial events	17	3.7	19	4.3
Polyps	8	1.7	7	1.6
Hemorrhage	2	0.4	3	0.7
Disorders	7	1.5	9	2.0
Subsequent cancers	12	2.6	8	1.8
Breast	3	0.7	1	0.2
Uterine	-	-	2	0.5
Gastrointestinal	3	0.7	1	0.2
Other	6	1.3	4	0.2
Cataracts	3	0.7	8	1.8
Increased liver enzyme levels	2	0.4	2	0.5
Bone fractures	13	2.8	5	1.1
Osteoporotic	2	0.4	3	0.7